| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 17 |
| 1 | BEVACIZUMAB | 16 |
| 2 | PACLITAXEL | 16 |
| 3 | PACLITAXEL (AIBUMIN-BOUND) | 16 |
| 4 | FLUOROURACIL | 12 |
| 5 | FLUOROURACIL CREAM, 0.5% | 12 |
| 6 | APIXABAN | 8 |
| 7 | DOSTARLIMAB | 8 |
| 8 | FUROSEMIDE | 8 |
| 9 | ALPRAZOLAM | 6 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | CAFFEINE, MAGNESIUM SALICYLATE | 1 | 0.0039 |
| 1 | DOSTARLIMAB | 8 | 0.0032 |
| 2 | PAMABROM | 1 | 0.0027 |
| 3 | MIRVETUXIMAB SORAVTANSINE | 1 | 0.0006 |
| 4 | VINBLASTINE SULFATE | 1 | 0.0005 |
| 5 | FLUDROCORTISONE ACETATE | 1 | 0.0004 |
| 6 | APREPITANT | 3 | 0.0004 |
| 7 | LEUCOVORIN CALCIUM | 6 | 0.0003 |
| 8 | ALUMINUM HYDROXIDE AND MAGNESIUM CARBONATE | 2 | 0.0003 |
| 9 | PEGFILGRASTIM | 3 | 0.0003 |
| # | Drug class | Count |
|---|---|---|
| 0 | Platinum-based Drug [EPC] | 22 |
| 1 | Microtubule Inhibitor [EPC] | 16 |
| 2 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 16 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 15 |
| 4 | Corticosteroid [EPC] | 12 |
| 5 | Factor Xa Inhibitor [EPC] | 11 |
| 6 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 11 |
| 7 | Loop Diuretic [EPC] | 8 |
| 8 | Benzodiazepine [EPC] | 6 |
| 9 | Proton Pump Inhibitor [EPC] | 6 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 1 | Substance P/Neurokinin-1 Receptor Antagonist [EPC] | 3 | 0.0003 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 11 | 0.0001 |
| 3 | Microtubule Inhibitor [EPC] | 16 | 0.0001 |
| 4 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 16 | 0.0001 |
| 5 | Platinum-based Drug [EPC] | 22 | 0.0001 |
| 6 | Epidermal Growth Factor Receptor Antagonist [EPC] | 3 | 0.0001 |
| 7 | Nucleoside Metabolic Inhibitor [EPC] | 15 | 0.0001 |
| 8 | CD52-directed Cytolytic Antibody [EPC] | 1 | 0.0001 |
| 9 | Estrogen Receptor Antagonist [EPC] | 2 | 0.0000 |